The aim of this study was to develop novel immunotherapeutic strategies for HNSCC employing CAR-NK cells that target HER1/epidermal growth factor receptor (EGFR), which is overexpressed in over 80% of HNSCC patients. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.